Using IHC analyses, we observed that increasing protein levels of CALCRL or ADM were associated with decreasing complete remission rates, inferior 5-year overall survival and event-free survival (EFS) in a cohort of 179 intensively treated AML patients (Fig. 1e, f). This evidence concerns the gene CALCRL and acute myeloid leukemia.